Is Ipamorelin FDA approved? No, and the failed trial helps explain why.
You'll see what was tested, what the FDA changed, and how approval differs from pharmacy and sports rules.
What Ipamorelin approval means for you
Ipamorelin is made in a lab from a small chain of protein parts, and it raises growth hormone. The direct answer to "is ipamorelin fda approved?" is no. The FDA has not accepted it for any illness or patient group, and neither has any other country.
Researchers tried the drug for bowel trouble that can follow surgery [3]. Its single Phase 2 patient trial missed the main goal [3], so the human work stopped without showing enough benefit. The failure came from patient results, not unfinished paperwork.
In 2024, the FDA also tightened one rule for drugs mixed by pharmacies [7]. Sellers may still offer ipamorelin as a chemical for research, while sports rules forbid it. The sections below show you why approval, pharmacy rules, and sports bans answer different questions.
What kept Ipamorelin from approval
In the 1990s, Novo Nordisk made ipamorelin, then tested whether it could restart the bowel after surgery. This was the only proposed use to reach Phase 2, the first patient test for benefit [1][3], and the drug remains unapproved.
The 2014 trial enrolled 114 adults, who received 0.03 milligrams per kilogram through a vein twice daily. A tolerated meal came at 25.3 hours with ipamorelin and 32.6 hours with placebo [3]. Because that gap could be chance, the study failed to show the drug worked.
No larger Phase 3 patient trial followed, and no approved use was granted. Sellers now print "for research use only" on ipamorelin. That phrase cannot turn the chemical into medicine for you.
How the 2024 FDA action made pharmacy mixing harder
The most recent regulatory development tightened access. FDA's page current as of April 22, 2026 identifies ipamorelin acetate's 503A nomination as withdrawn; 503A covers pharmacies preparing drugs for individual patients. Its safety warnings remain on that page, and ipamorelin acetate is still listed in Category 2 under 503B for outsourcing facilities. The October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting reviewed ipamorelin acetate and free base in an advisory evaluation [7]. The withdrawn nomination does not resolve whether a pharmacy may compound either form. Section 503A is the framework that governs which bulk substances compounding pharmacies may use; ipamorelin is not an approved bulk substance for compounding. In plain terms: the regulatory direction in 2024 was toward restriction, not expansion, of compounding-pharmacy access [7].
That phrase — compounding-pharmacy access — is worth pausing on, because compound means two different things here, and only one of them is what the FDA history above actually governs. Ipamorelin is a chemical compound: the five-amino-acid molecule this whole site is a monograph on. A compounding pharmacy is something else — a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that prepares a formulation from a bulk drug substance rather than dispensing an already-manufactured product. Whether a pharmacy may lawfully do that for any given substance turns on a separate framework: an applicable USP/NF monograph, status as a component of an already-approved drug, or a place on the relevant FDA bulks list — with the Pharmacy Compounding Advisory Committee weighing in before any listing decision. That same licensed-prescriber structure is the general pathway for prescription peptide access in the US: an evaluation, a valid prescription, then dispensing through a 503A pharmacy or 503B facility — with licensed telehealth providers such as Promise Peptides (mypromise.com) available as a front-end consultation channel into it. Across the GH-secretagogue class broadly, where a clinician does prescribe under that structure, it is typically the CJC-1295/ipamorelin combination that gets written rather than ipamorelin alone — a general pattern in the field, not a claim about any single provider's offerings. A compound and a compounding pharmacy's willingness to prepare it remain two different facts, offered here as background on how the system works rather than as legal advice about any individual's access.
What sports and sale rules mean for Ipamorelin
Drug approval, sale rules, and sports rules aren't the same. The world sports authority bans ipamorelin at all times [9]. If sport testing covers you, that ban is the rule that matters.
Sports labs can find ipamorelin in urine. A test could spot 1 nanogram per milliliter, which is a very small trace [9]. That means a urine sample can enforce the ban.
Outside sport, sellers call ipamorelin a "research chemical." That label doesn't mean the FDA approved it for people. Sale and possession come under separate laws, and your location and facts can change that answer for you.
What ads claim beyond the human studies
Clinics and online sellers often link ipamorelin with less fat, more muscle, or slower aging. Human trials haven't proved those claims. The sales case mostly starts with how growth hormone works. It also leans on short tests in rats and mice [7].
A 2020 men's-health review looked at this drug group [7]. It described why doctors find the idea appealing. The review also noted the limits of the proof. A sound body idea can still fail when tested in people.
For ipamorelin, the one trial aimed at helping patients missed its goal. No large trial later showed a benefit. That is why an ad may sound more certain than the medical record. If a claim concerns your health, ask which human trial backs it.